Aptevo Therapeutics (APVO) Net Equity Issued and Repurchased (2021 - 2026)

Aptevo Therapeutics has reported Net Equity Issued and Repurchased for 6 years, with the latest figure at $872000.0 in Q1 2026.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $872000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.3 million (up 177.46% YoY) and the FY2025 annual result came in at $37.9 million, up 278.04% from the prior year.
• Net Equity Issued and Repurchased retreated to $872000.0 in Q1 2026 per APVO's latest filing, from $32.1 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $32.1 million in Q4 2025 and troughed at -$1.6 million in Q3 2023.
• A 5-year average of $5.8 million and a median of $1.6 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2024 and 2025: Net Equity Issued and Repurchased slumped 95.51% in 2024, then surged 11982.71% in 2025.
• Over 5 years, Net Equity Issued and Repurchased stood at $6.6 million in 2022, then decreased by 9.69% to $5.9 million in 2023, then plunged by 95.51% to $266000.0 in 2024, then soared by 11982.71% to $32.1 million in 2025, then tumbled by 97.29% to $872000.0 in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $872000.0, $32.1 million, and $266000.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.